Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Liposarcoma (LPS) is a prevalent adult soft-tissue sarcoma (STS) with diverse histopathological and molecular features.
• Current treatments for advanced LPS are limited, with surgical resection being the primary approach for localized disease.
• The heterogeneity of LPS complicates the development of effective targeted therapies.

Purpose of the Study:

• To review the molecular genetics and epigenetic alterations in liposarcoma subtypes.
• To discuss key signaling pathways involved in LPS pathogenesis.
• To explore novel, biology-driven therapeutic strategies for LPS based on subtype-specific characteristics.

Main Methods:

• Comprehensive analysis of molecular genetics and epigenetic changes in liposarcoma.
• Review of signaling cascades implicated in liposarcoma development.
• Evaluation of emerging targeted therapies and their preclinical/clinical study status.

Main Results:

• Identification of specific molecular and epigenetic alterations across different liposarcoma subtypes.
• Elucidation of critical signaling pathways driving liposarcoma progression.
• Promising preclinical and clinical data for targeted agents, including CDK4/6 and MDM2 inhibitors, and multi-kinase inhibitors (anlotinib, sunitinib).

Conclusions:

• A deeper understanding of liposarcoma's molecular and epigenetic landscape is crucial for advancing treatment.
• Targeted therapies, particularly CDK4/6, MDM2 inhibitors, and multi-kinase inhibitors, show significant promise for LPS.
• Addressing treatment resistance and tumor heterogeneity is vital for successful clinical translation of novel therapies.